Press Releases

Mentice publishes information document regarding rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

Mentice receives an additional Subscription Commitment of 3.4 MSEK in the upcoming Rights Issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

Mentice resolves on a rights issue of approximately SEK 31.95 million

The Board of Directors of Mentice AB (publ) ("Mentice" or the "Company"), (Nasdaq First North Premium Growth Market) has today, based on the authorization granted by the annual general meeting on 27 May 2025, resolved on a rights issue of shares of approximately SEK 31.95 million before deduction of issue costs (the "Rights Issue"). The Company has received subscription undertakings from existing shareholders and members of the Board of Directors and management, for a total of approximately SEK 24.4 million, corresponding to approximately 76.5 percent of the Rights Issue. The purpose of the Rights Issue is primarily to strengthen the company´s financial position during the time under which the company is executing the realignment.

Mentice publishes the company’s interim report for the period April–June 2025

IMPORTANT STRATEGIC STEPS TAKEN

Mentice AB Announces Consolidation of Physical Simulation Operations to Strengthen Long-Term Efficiency and Global Service Delivery

Gothenburg, Sweden, July 11, 2025 - Mentice AB (publ), a global leader in simulation solutions for image-guided therapies, today announces the decision to consolidate its research and development (R&D) and manufacturing operations for its entire physical simulation portfolio to its new facility in Denver, Colorado, USA.

Mentice to Present Q2 2025 Interim Report via Webcast

Mentice AB (STO: MNTC) announces that the company will present its Q2 2025 Interim Report for the period April–June via a webcast conference call on Thursday, July 24, 2025, at 10:00 CEST.

Mentice AB announces the intent for a strategic workforce realignment to enhance focus and operational efficiency and the intent for a rights issue of max 10% of the share capital

Mentice AB (publ), a globally recognized leader in simulation solutions for image-guided interventional therapies, today announces the intent of a strategic workforce realignment and the intent of planning a rights issue of max 10% of the share capital aimed at optimizing its organizational structure and aligning resources with long-term business priorities.

Communique from annual general meeting in Mentice AB

An annual general meeting was held in Mentice AB on 27 May 2025. Below follows a summary of the resolutions made at the meeting.

Mentice Secures $642,000 Order from a Top 20 Global MedTech Company in Interventional Cardiology

Mentice Receives $642K Order to Advance Interventional Cardiology Training

Mentice Launch the latest version of Ankyras® in the United States Following FDA Clearance, Advancing Patient-Specific Aneurysm Planning for Neuro interventions

Gothenburg, Sweden, May 13, 2025, – Mentice, a globally recognized leader in simulation solutions for image-guided interventional therapies, announces that Ankyras® 4.0, its neurovascular clinical decision-support platform for patient-specific flow diverter planning, is now FDA 510(k) cleared and available for clinical use in the United States.

Mentice publishes the company’s interim report for the period January–March 2025

STABLE GROWTH AND STRATEGIC CHANGES IN THE FIRST QUARTER

Mentice Expands Ankyras® to Brazil Following Successful ANVISA Notification, Bringing Advanced Intracranial Aneurysm Treatment Planning to Latin America

Mentice AB (publ), Gothenburg – Mentice, a globally recognized leader in simulation solutions for image-guided interventional therapies, proudly announces that Ankyras®

Mentice to Present Q1 2025 Interim Report via Webcast

Mentice AB (STO: MNTC) announces that the company will present its Q1 2025 Interim Report for the period January–March via a webcast conference call on Thursday, May 8, 2025, at 10:00 CEST.

Mentice AB Publishes Annual and Sustainability Report for 2024 – Strong finish to 2024 following a transitional year

Mentice AB (publ), Gothenburg – a globally recognized leader in simulation solutions for image-guided interventional therapies, today published its Annual Report and Sustainability Report for 2024.

Annual shareholders’ meeting in Mentice AB

The shareholders in Mentice AB, reg. no. 566556-4241, (the “Company”), are hereby invited to attend the annual shareholders’ meeting to be held on 27 May 2025 at 1.00 p.m at Scandic Crown, Polhemsplatsen 3, 411 11 Gothenburg.

Mentice publishes the company’s year-end report for the period January–December 2024

STRONG CLOSING QUARTER

Mentice Secures $648,410 USD Combined Order for Advanced Simulation Solutions from a Top 20 Global MedTech company

Mentice (publ), Gothenburg, a globally recognized leader in simulation solutions for image-guided interventional therapies, announced today that it has secured a significant order from a top 20 global Med Tech company, a long-standing and valued customer.